CoreMedic announced that it picked up new funding in a Series B extension to support its transcatheter mitral valve repair ...

With new transcatheter options for the repair or replacement of tricuspid valves, the role and timing of repair — whether surgical or minimally invasive — is entering a time of transition.

The Heart Valve Devices Market is driven by advancements in aortic, mitral, tricuspid, and pulmonary valve technologies. It ...

Background Mitral valve repair (MVr) is the gold standard treatment for degenerative mitral regurgitation, yet there is ongoing controversy regarding optimal anti-thrombotic therapy post-MVr. This ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

A 78-year-old patient with severe mitral regurgitation has successfully undergone the MitraClip procedure, marking a ...

Q. I have a leaky heart valve that may need surgery down the road. Can you tell me about heart-valve surgery in one of your columns? A. First, let’s explain briefly how the heart works.

In a small series of LA appendage samples obtained during mitral valve replacement, patients with persistent AF were older and had larger LA when compared with patients in SR. They also had a higher ...

Bleakley Financial Group LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 5.3% during the 4th ...

"Don't be afraid to go to the doctor and get checked. But if you are it's ok. Just make sure you do it afraid, but ultimately, get it done," she says.

February is Heart Month, an effort to raise awareness of heart disease, the leading cause of death for both men and women.

Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong. The medical-technology company posted a profit of $385.6 million, or 65 cents a share, ...